## DEPARTMENT OF HEALTH & HUMAN SERVICES

Centers for Medicare & Medicaid Services 601 E. 12th St., Room 355 Kansas City, Missouri 64106



Medicaid and CHIP Operations Group

January 22, 2024

Michelle Baass Director and Interim State Medicaid Director California Department of Health Care Services P.O. Box 997413, MS 0000 Sacramento, CA 95899-7413

Re: California State Plan Amendment (SPA) 23-0044

## Dear Director Baass:

The Centers for Medicare & Medicaid Services (CMS) reviewed your Medicaid State Plan Amendment (SPA) submitted under transmittal number (TN) 23-0044. This amendment proposes to expand the prescribing authority for enteral formulae from physicians to include physicians, nurse practitioners, clinical nurse specialists, or physician assistants.

We conducted our review of your submittal according to statutory requirements in Title XIX of the Social Security Act and implementing regulations at 42 Code of Federal Regulations (CFR) 440.70. This letter is to inform you that California Medicaid SPA 23-0044 was approved on January 22, 2024, with an effective date of October 1, 2023.

If you have any questions, please contact Cheryl Young at 415-744-3598 or via email at Cheryl Young@cms.hhs.gov.

Sincerely,

Digitally signed by James G. Scott -S
Date: 2024.01.22
17:44:09 -06'00'

James G. Scott Director

James G. Scott, Director Division of Program Operations

Enclosures

CENTERS FOR MEDICARE & MEDICAID SERVICES	Oivid No. 0930-0193			
TRANSMITTAL AND NOTICE OF APPROVAL OF	1. TRANSMITTAL NUMBER 2. STATE			
STATE PLAN MATERIAL	$\frac{2}{3} - \frac{0}{0} + \frac{4}{4} = \frac{CA}{CA}$			
FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES	3. PROGRAM IDENTIFICATION: TITLE OF THE SOCIAL			
	SECURITY ACT  XIX  XXI			
TO: CENTER DIRECTOR	4. PROPOSED EFFECTIVE DATE			
CENTERS FOR MEDICAID & CHIP SERVICES	October 1, 2023			
DEPARTMENT OF HEALTH AND HUMAN SERVICES  5. FEDERAL STATUTE/REGULATION CITATION	6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars)			
42 CFR §440.120.70	a. FFY 2024 \$ 0			
	b. FFY 2025 \$ 0			
7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT	8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION			
Limitations on Attachment 3.1-A, page 14a	OR ATTACHMENT (If Applicable)			
Limitations on Attachment 3.1-B, page 14a	Limitations on Attachment 3.1-A, page 14a Limitations on Attachment 3.1-B, page 14a			
	Elithitations on Attachment 5.1-b, page 14a			
9. SUBJECT OF AMENDMENT	<u>. L</u>			
To expand the prescribing authority for enteral formulae, when sup	plied by a pharmacy provider, to include physician and			
non-physician prescriber types	product, a priarriady promacr, to morado priyociam and			
10. GOVERNOR'S REVIEW (Check One)				
O GOVERNOR'S OFFICE REPORTED NO COMMENT OTHER, AS SPECIFIED:				
O COMMENTS OF GOVERNOR'S OFFICE ENCLOSED	Please note: The Governor's Office does not wish to review			
O NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	the State Plan Amendment.			
11. SIGNATURE OF STATE AGENCY OFFICIAL	5. RETURN TO			
	epartment of Health Care Services			
	ttn: Director's Office			
Michelle Baass S	O. Box 997413, MS 0000 acramento, CA 95899-7413			
13. TITLE				
Director & Interim State Medicaid Director				
14. DATE SUBMITTED December 13, 2023				
FOR CMS USE ONLY				
16. DATE RECEIVED 1	7. DATE APPROVED			
December 13, 2023	January 22, 2024			
PLAN APPROVED - ONE COPY ATTACHED				
	9. SIG			
October 1, 2023				
20. TYPED NAME OF APPROVING OFFICIAL 2	APPROVING OFFICIAL 21. TITLE OF APPROVING OFFICIAL			
mes G. Scott Director, Division of Program Operations				
22. REMARKS				
Box 5: CMS pen and ink change to correct regulatory citation to 42 CFR 440.70 made per email from state dated 1/12/24.				
D				
Boxes 7-8: CMS pen and ink change to add additional SPA page per email from state dated 12/15/23.				

Limitations on Attachment 3.1-A Page 14a

(Note: This chart is an overview only)

TYPE OF SERVICE	PROGRAM COVERAGE**	PRIOR AUTHORIZATION OR OTHER REQUIREMENTS*
p a E	Covered only when supplied by a pharmacy provider as prescribed by a physician, nurse practitioner, clinical nurse specialist, or physician assistant within the scope of his or her practice.  Enteral Formulae commonly used in providing SNF and ICF level of care is not separately billable.	Prior authorization is required for all products. Authorization is given when the enteral formulae is used as a therapeutic regimen to prevent serious disability or death in patients with medically diagnosed conditions that preclude the full use of regular food.
	Common household items (food) are not covered.	Dietary supplements or products that cannot be used as a complete source of nutrition are considered non-benefits, except that the program may deem such a product a benefit when it determines that the use of the product is neither investigational nor experimental when used as a therapeutic regimen to prevent serious disability or death in patients with medically diagnosed conditions.
**Coverage is limited to med	quired for emergency services. ically necessary services.	
TN No. <u>23-0044</u> Supersedes TN No. <u>20-0035</u>	Approval Date: <u>January 22, 2024</u>	Effective Date: October 1. 2023

Limitations on Attachment 3.1-B Page 14a

(Note: This chart is an overview only)

TYPE OF SERVICE	PROGRAM COVERAGE**	PRIOR AUTHORIZATION OR OTHER
		REQUIREMENTS*
7c.3 Enteral Formulae	Covered only when supplied by a pharmacy provider as prescribed by a physician, nurse practitioner, clinical nurse specialist, or physician assistant within the scope of his or her practice.  Enteral Formulae commonly used in providing SNF and ICF level of care is not separately billable.	Prior authorization is required for all products. Authorization is given when the enteral formulae is used as a therapeutic regimen to prevent serious disability or death in patients with medically diagnosed conditions that preclude the full use of regular food.
	Common household items (food) are not covered.	Dietary supplements or products that cannot be used as a complete source of nutrition are considered non-benefits, except that the program may deem such a product a benefit when it determines that the use of the product is neither investigational nor experimental when used as a therapeutic regimen to prevent serious disability or death in patients with medically diagnosed conditions.

TN No. 23-0044 Supersedes TN No. <u>20-0035</u>

Approval Date: January 22, 2024 Effective Date: October 1, 2023

<sup>\*</sup>Prior authorization is not required for emergency services. \*\*Coverage is limited to medically necessary services.